Ultragenyx Pharmaceutical Lands $45,000,000 Series A Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=98aaee1a-8317-4e65-8cd2-556242497227&Preview=1 - Date
6/20/2011 - Company Name
Ultragenyx Pharmaceutical - Mailing Address
77 Digital Drive Novato, CA 94949 - Company Description
Ultragenyx is a new startup focused on developing therapeutics for rare diseases. The company is lead by Emil Kakkis, M.D., Ph.D., former CMO of BioMarin Pharmaceutical, and will build on management’s experience in choosing and developing products with clear mechanisms of action in untreated rare diseases. - Website
http://www.ultragenyx.com - Transaction Type
Venture Equity - Transaction Amount
$45,000,000 - Transaction Round
Series A - Proceeds Purposes
This funding will advance multiple rare disease product programs in the pipeline, as well as the development of new product candidates and partnerships. - M&A Terms
- Venture Investor
TPG Biotech - Venture Investor
Fidelity BioSciences - Venture Investor
Healthcap Venture Capital - Venture Investor
Pappas Ventures
